ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

baloxavir

Also written as “Baloxavir Marboxil” and “Baloxavir marboxil”.

Its studies are mostly in Influenza, Human, led by 2 companies.

Drug pageBaloxavir: every studyAll 20 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Aug 10, 201810 company-led studies, 2 open or runningNext primary completion: Apr 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Rocheits history only82 open or runningphase 3since Aug 10, 2018Aug 10, 2018Apr 30, 2027phase 3 · NCT07827599
Shionogiits history only20 open or runningphase 3since Oct 27, 2016Oct 27, 2016none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Oct 27, 2016First studies: 2 phase 3 studies in Influenza, HumanNew to ShionogiShionogi · NCT02954354, NCT02949011
  2. Dec 9, 2016Named baloxavirINNProposed as its International Nonproprietary Name in WHO's List 116
  3. Aug 10, 2018Hoffmann-La Roche’s first studies: 2 phase 3 studies in Influenza, HumanNew to Hoffmann-La RocheHoffmann-La Roche · NCT03629184, NCT03653364
  4. Sep 24, 2018Phase 3 study in Influenza, HumanHoffmann-La Roche · NCT03684044 · 363 enrolled · United States, Argentina, Australia and more
  5. May 21, 2019No phase study in Healthy VolunteerHoffmann-La Roche · NCT03959332 · 32 enrolled · China
  6. May 29, 2019Phase 3 study in Influenza, HumanHoffmann-La Roche · NCT03969212 · 4,138 enrolled · United States, Bulgaria, China and more
  7. Oct 17, 2023Phase 3 study in Influenza, HumanHoffmann-La Roche · NCT06094010 · 1,100 planned · United States, Bulgaria, Poland and more
  8. Jan 9, 2025Phase 3 study in Influenza, HumanHoffmann-La Roche · NCT06774859 · 100 enrolled · China
  9. Sep 15, 2026Phase 3 study in Influenza, HumanHoffmann-La Roche · NCT07827599 · 325 planned · China

Ahead

  1. Apr 30, 2027Primary completion: phase 3 study in Influenza, HumanHoffmann-La Roche · NCT07827599
  2. May 11, 2027Primary completion: phase 3 study in Influenza, HumanHoffmann-La Roche · NCT06094010

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Polymerase acidic protein inhibitor; Polymerase acidic protein inhibitor”ChEMBL 37, by rule

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07827599Influenza, Human · China3RecruitingHoffmann-La RocheApr 30, 2027325
NCT06774859Influenza, Human · China3CompletedHoffmann-La RocheMay 8, 2025100
NCT06094010Influenza, Human · United States, Bulgaria, Poland and more3RecruitingHoffmann-La RocheMay 11, 20271,100
NCT03969212Influenza, Human · United States, Bulgaria, China and more3CompletedHoffmann-La RocheMay 10, 20244,138
NCT03959332Healthy Volunteer · China–CompletedHoffmann-La RocheJul 11, 201932
NCT03684044Influenza, Human · United States, Argentina, Australia and more3CompletedHoffmann-La RocheMar 16, 2020363
NCT03653364Influenza, Human · United States, Bulgaria, Costa Rica and more3CompletedHoffmann-La RocheApr 3, 202349
NCT03629184Influenza, Human · United States, Costa Rica, Israel and more3CompletedHoffmann-La RocheApr 3, 2019173
NCT02954354Influenza, Human3CompletedShionogiApr 4, 20171,436
NCT02949011Influenza, Human3CompletedShionogiApr 12, 20182,184

How it is read

Names in the registry

  • “Baloxavir Marboxil”, 9 entries
  • “Baloxavir marboxil”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.